Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05303532




Registration number
NCT05303532
Ethics application status
Date submitted
4/02/2022
Date registered
31/03/2022
Date last updated
14/06/2024

Titles & IDs
Public title
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Scientific title
ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Secondary ID [1] 0 0
2021-003031-29
Secondary ID [2] 0 0
D4191C00137
Universal Trial Number (UTN)
Trial acronym
ROSY-D
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Durvalumab

Experimental: Durvalumab - Participants will receive durvalumab.


Treatment: Drugs: Durvalumab
Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Timepoint [1] 0 0
From baseline up to follow up at 90 days after the last dose of study drug.

Eligibility
Key inclusion criteria
The Core Protocol inclusion criteria are:

* Provision of signed and dated, written Informed Consent Form (ICF).
* Patient is currently deriving clinical benefit, as judged by the investigator, from continued treatment in an AstraZeneca parent study using an AstraZeneca compound that has met its endpoints, or has otherwise stopped, or the patient has reached maximum treatment duration allowed in the parent study's protocol.
* Patient can receive durvalumab as a fixed dose of 1500 mg quarterly 4 weeks at study entry.

There are no additional inclusion criteria for the ROSY-D sub-study.
Minimum age
18 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
The Core Protocol exclusion criteria are.

* Ongoing, unresolved, Grade 3 or above toxicity requiring interruption of treatment at the time of the termination of the parent study.
* Currently receiving treatment with any prohibited medication(s).
* Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
* Permanent discontinuation from the parent study due to toxicity or disease progression (increase in the severity of the disease under study and/or increases in the symptoms of a patient's condition attributable to the disease, as assessed and documented by the Investigator. Physician-defined progression can be radiological [example: Response Evaluation Criteria in Solid Tumours] progression or clinical progression).
* Local access to commercially-available drug at no cost to the patient as permitted by local/country regulation.

The additional exclusion criteria for the ROSY-D sub-study are:

* Active infection including Coronavirus disease 2019 (Polymerase chain reaction confirmed and/or clinically suspected), tuberculosis, hepatitis B (known positive Hepatitis B virus (HBV) surface antigen result), hepatitis C, or Human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies).
* Male or female patients of reproductive potential who are not willing to employ effective birth control from study inclusion up to 90 days after the last dose of durvalumab monotherapy.
* Ongoing, unresolved, Grade 2 toxicity with an inability to reduce corticosteroid to a dose of = 10 mg of prednisone per day (or equivalent) within 12 weeks after last dose of study treatment/study regimen, per Toxicity Dose Modification and TMGs for Immune- mediated, Infusion-related, and Non-Immune-mediated Reactions Guidelines of the parent study.

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/04/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
8/05/2025
Actual
Sample size
Target
61
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Box Hill
Recruitment hospital [2] 0 0
Research Site - Melbourne
Recruitment postcode(s) [1] 0 0
3128 - Box Hill
Recruitment postcode(s) [2] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
New York
Country [3] 0 0
United States of America
State/province [3] 0 0
Tennessee
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
Argentina
State/province [5] 0 0
Rosario
Country [6] 0 0
Belgium
State/province [6] 0 0
Charleroi
Country [7] 0 0
Brazil
State/province [7] 0 0
Barretos
Country [8] 0 0
Brazil
State/province [8] 0 0
Porto Alegre
Country [9] 0 0
Brazil
State/province [9] 0 0
São José do Rio Preto
Country [10] 0 0
Bulgaria
State/province [10] 0 0
Sofia
Country [11] 0 0
Canada
State/province [11] 0 0
Ontario
Country [12] 0 0
China
State/province [12] 0 0
Beijing
Country [13] 0 0
China
State/province [13] 0 0
Changsha
Country [14] 0 0
China
State/province [14] 0 0
Hangzhou
Country [15] 0 0
China
State/province [15] 0 0
Jinan
Country [16] 0 0
China
State/province [16] 0 0
Nanjing
Country [17] 0 0
China
State/province [17] 0 0
Shanghai
Country [18] 0 0
China
State/province [18] 0 0
Shijiazhuang
Country [19] 0 0
China
State/province [19] 0 0
Xi'an
Country [20] 0 0
Czechia
State/province [20] 0 0
Olomouc
Country [21] 0 0
France
State/province [21] 0 0
Besançon Cedex
Country [22] 0 0
France
State/province [22] 0 0
Bordeaux Cedex
Country [23] 0 0
France
State/province [23] 0 0
Brest
Country [24] 0 0
France
State/province [24] 0 0
Dijon cedex
Country [25] 0 0
France
State/province [25] 0 0
Lyon
Country [26] 0 0
France
State/province [26] 0 0
Marseille
Country [27] 0 0
France
State/province [27] 0 0
Montpellier
Country [28] 0 0
France
State/province [28] 0 0
Rouen
Country [29] 0 0
France
State/province [29] 0 0
Saint Herblain
Country [30] 0 0
France
State/province [30] 0 0
Strasbourg
Country [31] 0 0
France
State/province [31] 0 0
Toulouse Cedex 09
Country [32] 0 0
France
State/province [32] 0 0
Tours CEDEX
Country [33] 0 0
France
State/province [33] 0 0
Villejuif
Country [34] 0 0
Germany
State/province [34] 0 0
Guetersloh
Country [35] 0 0
Germany
State/province [35] 0 0
Muenster
Country [36] 0 0
Hungary
State/province [36] 0 0
Budapest
Country [37] 0 0
Hungary
State/province [37] 0 0
Gyor
Country [38] 0 0
Hungary
State/province [38] 0 0
Székesfehérvár
Country [39] 0 0
India
State/province [39] 0 0
Chennai
Country [40] 0 0
Italy
State/province [40] 0 0
Arezzo
Country [41] 0 0
Italy
State/province [41] 0 0
Bari
Country [42] 0 0
Italy
State/province [42] 0 0
Catania
Country [43] 0 0
Italy
State/province [43] 0 0
Meldola
Country [44] 0 0
Italy
State/province [44] 0 0
Milano
Country [45] 0 0
Italy
State/province [45] 0 0
Milan
Country [46] 0 0
Italy
State/province [46] 0 0
Modena
Country [47] 0 0
Italy
State/province [47] 0 0
Padova
Country [48] 0 0
Italy
State/province [48] 0 0
Pisa
Country [49] 0 0
Italy
State/province [49] 0 0
Roma
Country [50] 0 0
Japan
State/province [50] 0 0
Bunkyo-ku
Country [51] 0 0
Japan
State/province [51] 0 0
Kanazawa-shi
Country [52] 0 0
Japan
State/province [52] 0 0
Koto-ku
Country [53] 0 0
Japan
State/province [53] 0 0
Nagasaki-shi
Country [54] 0 0
Japan
State/province [54] 0 0
Nagoya-shi
Country [55] 0 0
Japan
State/province [55] 0 0
Saga-shi
Country [56] 0 0
Japan
State/province [56] 0 0
Sunto-gun
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Busan
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Gwangju
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Seoul
Country [60] 0 0
Malaysia
State/province [60] 0 0
Kuching
Country [61] 0 0
Poland
State/province [61] 0 0
Bialystok
Country [62] 0 0
Poland
State/province [62] 0 0
Olsztyn
Country [63] 0 0
Poland
State/province [63] 0 0
Szczecin
Country [64] 0 0
Poland
State/province [64] 0 0
Lódz
Country [65] 0 0
Romania
State/province [65] 0 0
Suceava
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Moscow
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Nizhniy Novgorod
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Novosibirsk
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Obninsk
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Omsk
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Saint Petersburg
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Saint-Petersburg
Country [73] 0 0
Spain
State/province [73] 0 0
Barcelona
Country [74] 0 0
Spain
State/province [74] 0 0
Girona
Country [75] 0 0
Spain
State/province [75] 0 0
Madrid
Country [76] 0 0
Spain
State/province [76] 0 0
Marbella
Country [77] 0 0
Spain
State/province [77] 0 0
Santiago de Compostela
Country [78] 0 0
Spain
State/province [78] 0 0
Valencia
Country [79] 0 0
Switzerland
State/province [79] 0 0
Lausanne
Country [80] 0 0
Taiwan
State/province [80] 0 0
Taichung
Country [81] 0 0
Taiwan
State/province [81] 0 0
Tainan
Country [82] 0 0
Taiwan
State/province [82] 0 0
Taipei City
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taoyuan
Country [84] 0 0
Thailand
State/province [84] 0 0
Bangkok
Country [85] 0 0
Thailand
State/province [85] 0 0
Chiang Mai
Country [86] 0 0
Thailand
State/province [86] 0 0
Hat Yai
Country [87] 0 0
Turkey
State/province [87] 0 0
Ankara
Country [88] 0 0
Turkey
State/province [88] 0 0
Bursa
Country [89] 0 0
Turkey
State/province [89] 0 0
Istanbul
Country [90] 0 0
Turkey
State/province [90] 0 0
Izmir
Country [91] 0 0
Turkey
State/province [91] 0 0
Çankaya
Country [92] 0 0
Ukraine
State/province [92] 0 0
Chernivtsi
Country [93] 0 0
Ukraine
State/province [93] 0 0
Dnipro
Country [94] 0 0
Ukraine
State/province [94] 0 0
Ivano-Frankivsk
Country [95] 0 0
Ukraine
State/province [95] 0 0
Kyiv
Country [96] 0 0
Ukraine
State/province [96] 0 0
Uzhhorod
Country [97] 0 0
Ukraine
State/province [97] 0 0
Vinnytsia
Country [98] 0 0
United Kingdom
State/province [98] 0 0
London
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Sheffield
Country [100] 0 0
Vietnam
State/province [100] 0 0
Hanoi
Country [101] 0 0
Vietnam
State/province [101] 0 0
Ho Chi Minh city
Country [102] 0 0
Vietnam
State/province [102] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
Trial website
https://clinicaltrials.gov/study/NCT05303532
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05303532